Bone Metastasis Market Research Report - Forecast to 2027

Bone Metastasis Market Research Report, by Type (Osteolytic, Osteoblastic, Mixed), Diagnosis (Biopsy, Blood Test, Imaging), Treatment (Medical Therapies, Surgery, Medication), End User (Hospital, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/Pharma/4321-HCR | February 2021 | Region: Global | 90 pages

Bone Metastasis Market Scenario


Bone metastasis is characterized by the spreading of cancerous cells from their original site to a bone. All types of cancer can show bone-metastasis. However, it is estimated that breast cancer and prostate cancer are commonly associated with the disease. The medical condition is frequent for spine, pelvis, and thighs. Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease. The increasing prevalence of bone metastasis is expected to be a major driver for the market growth during the forecast period. According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively. Moreover, the growing geriatric population, increasing healthcare expenditures, and increasing R&D in the market are estimated to drive the market growth during the forecast period. According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more. However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.


The bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast period 


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1: Bone Metastasis Market Share, by Region


 Bone Metastasis Market Share


Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation


Segmentation


The bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the bone metastasis market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.


On the basis of diagnosis, the bone metastasis market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.


On the basis of the treatment, the bone metastasis market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.


On the basis of end-user, the bone metastasis market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.

Research Methodology


Methodology


Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation


Regional Analysis


America dominates the bone metastasis market. This can be attributed to the presence of a well-developed healthcare sector, the increasing prevalence of breast cancer, and increasing healthcare sector within the region. Moreover, the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the regional market growth.


Europe is the second in the bone metastasis market owing to the availability of funds for research and a huge patient population. According to the Cancer Research U.K., approximately 55,122 new cases of invasive breast cancer were reported in 2015. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe leads the regional market due to the presence of developed economies within the region.


Asia Pacific is projected to be the fastest growing region in the bone metastasis market. The presence of developing economies such as India and China, a developing healthcare sector, and the growing prevalence of cancer within the region drive the market growth in the region. Moreover, favorable government policies and increasing penetration of key market players within the region fuel the market growth.


The Middle East and Africa holds the least share in the bone metastasis market, owing to the presence of poor economies, stringent government policies, and lack of healthcare services, especially within the African region. A majority of the market of bone metastasis in the Middle East and Africa is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure by developed economies such as Saudi Arabia, Kuwait, Dubai, and others within the region.

Key players


The key players in the bone metastasis market are F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.4% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of bone metastasis
  • Growing geriatric population
  • Increasing healthcare expenditures
  • Increasing R&D


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Bone metastasis is the condition when cancerous cells from other sites migrate to a bone.

    Market is expected to exhibit a strong 8.4% CAGR over the forecast period till 2027.

    Increasing prevalence of cancer is likely to be a major driver for the Bone Metastasis Market.

    Americas hold the largest share in the Bone Metastasis Market.

    Leading players in the Bone Metastasis Market include Merck, Bayer, and Pfizer, among others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Bone Metastasis Market, by Type

    6.1 Introduction

    6.2 Osteolytic Bone Metastasis

    Market Estimates & Forecast, 2020–2027

    6.3 Osteoblastic Bone Metastasis

    Market Estimates & Forecast, 2020–2027

    6.4 Mixed Bone Metastasis

    Market Estimates & Forecast, 2020–2027

    6.5 Others

    Chapter 7. Global Bone Metastasis Market, by Diagnosis

    7.1 Introduction

    7.2 Biopsy

    Market Estimates & Forecast, 2020–2027

    7.3 Blood Test

    Market Estimates & Forecast, 2020–2027

    7.4 Imaging

    Market Estimates & Forecast, 2020–2027

    7.4.1 X-ray

    7.4.2 Bone Scintigraphy

    7.4.3 Computerized Tomography

    7.4.4 Magnetic Resonance Imaging

    7.4.5 Positron Emission Tomography

    7.4.6 Others

    7.5 Others

    Chapter 8. Global Bone Metastasis Market, by Treatment

    8.1 Introduction

    8.2 Medical Therapies

    Market Estimates & Forecast, 2020–2027

    8.2.1 Chemotherapy

    8.2.2 Targeted therapy

    8.2.3 Hormone therapy

    8.2.4 Ablation Therapy

    Market Estimates & Forecast, 2020–2027

    8.2.4.1 Radiofrequency Ablation

    8.2.4.2 Cryoablation

    8.2.4.3 Others

    8.2.5 Others

    8.3 Surgery

    Market Estimates & Forecast, 2020–2027

    8.3.1 Vertebroplasty

    8.3.2 Kyphoplasty

    8.4 Medication

    Market Estimates & Forecast, 2020–2027

    8.4.1 Pain Medications

    Market Estimates & Forecast, 2020–2027

    8.4.1.1 Ibuprofen

    8.4.1.2 Morphine

    8.4.1.3 Others

    8.4.2 Bone-Building Medications

    Market Estimates & Forecast, 2020–2027

    8.4.2.1 Corticosteroids

    8.4.2.2 Bisphosphonates

    Market Estimates & Forecast, 2020–2027

    8.4.2.2.1 Teriparatide

    8.4.2.2.2 Pamidronate

    8.4.2.2.3 Medronate

    8.5 Others

    Chapter 9. Global Bone Metastasis Market, by End-User

    9.1 Introduction

    9.2 Hospital & Clinics

    Market Estimates & Forecast, 2020–2027

    9.3 Diagnostic Centers

    Market Estimates & Forecast, 2020–2027

    9.4 Pharmacies

    Market Estimates & Forecast, 2020–2027

    9.5 Ambulatory Surgical Centers

    Market Estimates & Forecast, 2020–2027

    9.6 Others

    Chapter 10. Global Bone Metastasis Market, by Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K.

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 F. Hoffmann-La Roche Ltd

    12.1.1 Company Overview

    12.1.2 Type Overview

    12.1.3 Financials

    12.2.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Bayer AG

    12.2.1 Company Overview

    12.2.2 Type Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Merck & Co., Inc.

    12.3.1 Company Overview

    12.3.2 Type Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Pfizer Inc.

    12.4.1 Company Overview

    12.4.2 Type/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Novartis AG

    12.5.1 Company Overview

    12.5.2 Type Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Pharmalucence Inc.

    12.6.1 Company Overview

    12.6.2 Type Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Koninklijke Philips N.V.

    12.7.1 Overview

    12.7.2 Type Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 GENERAL ELECTRIC

    12.8.1 Overview

    12.8.2 Type Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Siemens AG

    12.9.1 Overview

    12.9.2 Type Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 TOSHIBA CORPORATION

    12.10.1 Overview

    12.10.2 Type Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Bone Metastasis Market

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Bone Metastasis Industry Synopsis, 2020–2027

    Table 2 Global Bone Metastasis Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Bone Metastasis Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 5 Global Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 6 Global Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 7 Global Bone Metastasis Market, by End-User, 2020–2027, (USD Million

    Table 8 North America Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 9 North America Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 10 North America Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 11 North America Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 12 U.S. Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 13 U.S. Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 14 U.S. Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 15 U.S. Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 16 Canada Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 17 Canada Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 18 Canada Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 19 Canada Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 20 South America Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 21 South America Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 22 South America Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 23 South America Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 24 Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 25 Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 26 Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 27 Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 28 Western Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 29 Western Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 30 Western Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 31 Western Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 32 Eastern Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 33 Eastern Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 34 Eastern Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 35 Eastern Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 36 Asia Pacific Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 37 Asia Pacific Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 38 Asia Pacific Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 39 Asia Pacific Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    Table 40 The Middle East & Africa Bone Metastasis Market, by Type, 2020–2027, (USD Million)

    Table 41 The Middle East & Africa Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 42 The Middle East & Africa Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

    Table 43 The Middle East & Africa Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Bone Metastasis Market

    Figure 3 Market Dynamics for Global Bone Metastasis Market

    Figure 4 Global Bone Metastasis Market Share, by Type 2020

    Figure 5 Global Bone Metastasis Market Share, by Diagnosis 2020

    Figure 6 Global Bone Metastasis Market Share, by Treatment, 2020

    Figure 7 Global Bone Metastasis Market Share, by End-User, 2020

    Figure 8 Global Bone Metastasis Market Share, by Region, 2020

    Figure 9 North America Bone Metastasis Market Share, by Country, 2020

    Figure 10 Europe Bone Metastasis Market Share, by Country, 2020

    Figure 11 Asia Pacific Bone Metastasis Market Share, by Country, 2020

    Figure 12 The Middle East & Africa Bone Metastasis Market Share, by Country, 2020

    Figure 13 Global Bone Metastasis Market: Company Share Analysis, 2020 (%)

    Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

    Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

    Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

    Figure 17 Bayer AG: Key Financials

    Figure 18 Bayer AG: Segmental Revenue

    Figure 19 Bayer AG: Geographical Revenue

    Figure 20 Merck & Co., Inc.: Key Financials

    Figure 21 Merck & Co., Inc.: Segmental Revenue

    Figure 22 Merck & Co., Inc.: Geographical Revenue

    Figure 23 Pfizer Inc.: Key Financials

    Figure 24 Pfizer Inc.: Segmental Revenue

    Figure 25 Pfizer Inc.: Geographical Revenue

    Figure 26 Novartis AG: Key Financials

    Figure 27 Novartis AG: Segmental Revenue

    Figure 28 Novartis AG: Geographical Revenue

    Figure 29 Pharmalucence Inc.: Key Financials

    Figure 30 Pharmalucence Inc.: Segmental Revenue

    Figure 31 Pharmalucence Inc.: Geographical Revenue

    Figure 32 Koninklijke Philips N.V.: Key Financials

    Figure 33 Koninklijke Philips N.V.: Segmental Revenue

    Figure 34 Koninklijke Philips N.V.: Geographical Revenue

    Figure 35 GENERAL ELECTRIC: Key Financials

    Figure 36 GENERAL ELECTRIC: Segmental Revenue

    Figure 37 GENERAL ELECTRIC: Geographical Revenue

    Figure 38 Siemens AG: Key Financials

    Figure 39 Siemens AG: Segmental Revenue

    Figure 40 Siemens AG: Geographical Revenue

    Figure 41 TOSHIBA CORPORATION: Key Financials

    Figure 42 TOSHIBA CORPORATION: Segmental Revenue

    Figure 43 TOSHIBA CORPORATION: Geographical Revenue